Helping Alaska Native people quit smoking using a personalized approach

Metabolism-Informed Care to Aid Alaska Native People to Quit Smoking (QUIT): Pilot Intervention and Assessment of Barriers and Facilitators of Implementation

This study is testing a personalized method to help Alaska Native and American Indian people quit smoking by using their body’s response to nicotine to create tailored treatment plans.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 50 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Southcentral Foundation (other)
• Locations: 1 site (Anchorage, Alaska)
• Trial ID: NCT06556238 on ClinicalTrials.gov

What this trial studies

This intervention focuses on using the Nicotine Metabolite Ratio (NMR) to tailor pharmacologic treatments for smoking cessation among Alaska Native and American Indian individuals. It is a single-arm pilot trial aimed at assessing the acceptability and feasibility of this personalized approach. Participants will undergo blood tests and provide saliva samples to inform their treatment plans, and they must be willing to attempt quitting smoking within 30 days of enrollment. The study is conducted in collaboration with Southcentral Foundation and aims to improve smoking abstinence rates in this population.

Who should consider this trial

Good fit: Ideal candidates are Alaska Native or American Indian adults who are daily smokers and are planning to seek smoking cessation treatment.

Not a fit: Patients who do not identify as Alaska Native or American Indian or those who are not daily smokers may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could significantly enhance smoking cessation rates among Alaska Native and American Indian populations.

How similar studies have performed: While this specific approach is novel, similar studies have shown promise in using personalized treatment strategies for smoking cessation.

Eligibility criteria

Inclusion Criteria:

(Patients)

* Alaska Native or American Indian person by self-report
* eligible for or already receiving services at Southcentral Foundation (SCF)
* age 18 years or older
* daily smoking in the past 30-days
* if other nicotine or tobacco products are used, cigarettes are main product used
* planning to schedule an appointment with the Quit Tobacco Program to seek smoking cessation treatment in the next 30 days
* willing to make a quit attempt within 30 days of enrollment in the Quit Tobacco Program
* willing to have a blood test to inform their treatment
* willing to try a pharmacologic treatment
* willing to provide a saliva sample
* has phone service
* has access to broadband internet on mobile phone at home, work, or other location
* has an Android or iPhone mobile phone compatible with the Smokerlyzer app

(Staff)

\- Staff participants of qualitative interviews to assess acceptability and feasibility of the intervention must be a health care professional at Southcentral Foundation (SCF), involved in the care of one of the participants of the study, that is their care team staff; including but not limited to: primary care providers, tobacco treatment specialists/health educators, pharmacists, nurse case managers, behavioral health consultants, certified medical assistants, and lab technicians.

Exclusion Criteria:

(Patients)

* Participated in the prior study phase
* participated in a cessation program during the past 3 months
* their provider has not approved varenicline in their referral to the Quit Tobacco Program
* has history of serious hypersensitivity or skin reactions to varenicline
* has bleeding disorder or is currently receiving cancer treatment
* questionable capacity or impaired decision-making capacity

Where this trial is running

Anchorage, Alaska

• Anchorage Native Primary Care Center — Anchorage, Alaska, United States (RECRUITING)

Study contacts

• Principal investigator: Georgia J Michlig, PhD — Southcentral Foundation
• Study coordinator: Georgia Michlig, PhD

Conditions: Smoking Cessation